Evidence map›Paper›PMID 31350550›Full record

ArticleCardiovascular research2020

Statistics on mortality following acute myocardial infarction in 842 897 Europeans.

Oras A Alabas, Tomas Jernberg, Mar Pujades-Rodriguez, Mark J Rutherford, Robert M West, Marlous Hall, Adam Timmis, Bertil Lindahl, Keith A A Fox, Harry Hemingway and 1 more

Open access · bronzeAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. OECD indicator 'AMI 30-day mortality' is neither comparable between countries nor suitable as indicator for quality of acute care.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Oras A AlabasLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Tomas JernbergDepartment of clinical sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden.
Mar Pujades-RodriguezLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Mark J RutherfordDepartment of Health Sciences, University of Leicester, Leicester, UK.
Robert M WestLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Marlous HallLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Adam TimmisDepartment of Cardiology, Barts Heart Centre, London, UK.
Bertil LindahlDepartment of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Keith A A FoxCentre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
Harry HemingwayHealth Data Research UK London, University College London, London, UK.
Chris P GaleLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
University of Leeds · GBBritish Heart Foundation · GBKarolinska University Hospital · SEUniversity of Edinburgh · GBUniversity of Leicester · GBUniversity of London · GBUppsala University · SE

Funding

Wellcome Trust 206470Wellcome Trust 206470/Z/17/Z
6 · The paper itself

Abstract

aimsTo compare ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) mortality between Sweden and the UK, adjusting for background population rates of expected death, case mix, and treatments. METHODS AND

resultsNational data were collected from hospitals in Sweden [n = 73 hospitals, 180 368 patients, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)] and the UK [n = 247, 662 529 patients, Myocardial Ischaemia National Audit Project (MINAP)] between 2003 and 2013. There were lower rates of revascularization [STEMI (43.8% vs. 74.9%); NSTEMI (27.5% vs. 43.6%)] and pharmacotherapies at time of hospital discharge including [aspirin (82.9% vs. 90.2%) and (79.9% vs. 88.0%), β-blockers (73.4% vs. 86.4%) and (65.3% vs. 85.1%)] in the UK compared with Sweden, respectively. Standardized net probability of death (NPD) between admission and 1 month was higher in the UK for STEMI [8.0 (95% confidence interval 7.4-8.5) vs. 6.7 (6.5-6.9)] and NSTEMI [6.8 (6.4-7.2) vs. 4.9 (4.7-5.0)]. Between 6 months and 1 year and more than 1 year, NPD remained higher in the UK for NSTEMI [2.9 (2.5-3.3) vs. 2.3 (2.2-2.5)] and [21.4 (20.0-22.8) vs. 18.3 (17.6-19.0)], but was similar for STEMI [0.7 (0.4-1.0) vs. 0.9 (0.7-1.0)] and [8.4 (6.7-10.1) vs. 8.3 (7.5-9.1)].

conclusionShort-term mortality following STEMI and NSTEMI was higher in the UK compared with Sweden. Mid- and longer-term mortality remained higher in the UK for NSTEMI but was similar for STEMI. Differences in mortality may be due to differential use of guideline-indicated treatments.

Indexed as

AdolescentAdultAgedAged, 80 and overCardiovascular AgentsCause of DeathFemaleGuideline AdherenceHealthcare DisparitiesHumansMaleMiddle AgedMyocardial RevascularizationNon-ST Elevated Myocardial InfarctionPractice Guidelines as TopicPractice Patterns, Physicians'Cardiovascular AgentsAcute myocardial infarctionMINAPMortalitySWEDEHEARTSwedenUK

Identifiers

PMID31350550
PMCPMC7618253
OpenAlexW2964636773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.